From these results, a lead molecule PH46A (1) demonstrated efficacy in two murine models of inflammatory bowel disease (IBD): an acute dextran sulphate sodium (DSS) model of murine colitis and the more chronic spontaneous model of IL-10−/− colitis mice.[4] The scaffold of PH46A (1) incorporates the indane skeleton and is the N-glucamine salt of a single enantiomer PH46 (2) of this novel drug with 1S, 2S stereochemistry at the C-1 and C-2 positions. Here, IL10 is linked to inflammatory bowel disease.